Evaluating vaccine technologies using mouse models for coronavirus immunity.
Task A68: Screening Vaccine (and Other Biologics) Platform Technologies using Coronavirus Mouse Immunogenicity as a Model System
This study is looking at how well different vaccine options work to boost the immune response against coronaviruses using mice, with the hope that successful findings could help improve vaccines for everyone.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-11066399 on NIH RePORTER |
What this research studies
This research focuses on developing and refining models to study infectious diseases, specifically using mice to evaluate the immunogenicity of vaccine candidates against coronaviruses. By testing various vaccine platforms and biologics, the research aims to identify effective countermeasures that could enhance immune responses. Patients may benefit indirectly as successful vaccine technologies could lead to better prevention strategies against infectious diseases, including coronaviruses.
Who could benefit from this research
Good fit: Ideal candidates for benefiting from this research include individuals at risk for coronavirus infections, such as those with underlying health conditions or in high-exposure environments.
Not a fit: Patients who are not at risk for infectious diseases or those who have already been vaccinated against coronaviruses may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective vaccines against coronaviruses, improving public health outcomes.
How similar studies have performed: Previous research has shown success in using animal models to evaluate vaccine efficacy, indicating that this approach is well-established.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Baric, Ralph — Univ of North Carolina Chapel Hill
- Study coordinator: Baric, Ralph
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.